Dihydronaphthyridine Kinase Inhibitors Overcoming c-KIT Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastrointestinal stromal tumors (GIST) and other c-KIT mutation-related diseases face challenges due to the development of secondary mutations that confer resistance to existing inhibitors, necessitating a broad-spectrum c-KIT kinase inhibitor effective across various primary and secondary mutations.
Innovation Solution
Development of novel compounds, specifically represented by Formula Ia, which inhibit c-KIT kinase across a range of mutations, including those in exons 9, 11, 13, 14, and 17, including the resistant D816V mutation, for treating refractory GIST and other c-KIT mutation-driven diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing c-KIT kinase inhibitors are used to treat GIST, then initial therapeutic effect is achieved, but secondary mutations develop that confer resistance to the inhibitors
Solution Approach 1:
The patent employs parameter changes by developing compounds with modified chemical structures (Formula Ia with specific substituents A, G1, G4, Z1-Z3, R1-R7) that alter the binding characteristics to overcome resistance. The structural variations in the naphthyridine core and substituent patterns enable the compound to maintain inhibitory activity against mutants that have developed resistance to prior inhibitors.
Solution Approach 2:
The invention achieves universality by designing a broad-spectrum c-KIT kinase inhibitor that functions against multiple mutation types simultaneously. The compound demonstrates activity against primary mutations (exons 9, 11) and secondary mutations (exons 13, 14, 17 including D816V), making it a multi-functional agent that addresses diverse resistance mechanisms with a single therapeutic.
2Adaptability or versatility
If a broad-spectrum c-KIT kinase inhibitor is developed to cover multiple mutations, then therapeutic coverage is improved, but the complexity of the compound structure increases
Solution Approach 1:
The patent systematically varies chemical parameters within the Formula Ia structure to achieve broad mutation coverage. By modifying specific positions (A as phenyl/naphthyl/benzothienyl, G1 as various heteroaryls, G4 as heterocyclyls, and substituents Z1-Z3 and R1-R7), the invention creates a series of related compounds that maintain a core pharmacophore while adapting to different mutation types through controlled structural parameter changes.
3Ease of operation
If existing therapies are used for refractory GIST, then treatment is provided, but resistance to therapy persists
Solution Approach 1:
The patent applies preliminary action by developing a next-generation inhibitor that is designed in advance to overcome resistance mechanisms. Rather than waiting for resistance to develop, the compound is proactively designed with structural features that anticipate and counteract secondary mutation development, providing effective treatment for refractory cases before resistance fully establishes.
Data Source
AI summary
The invention relates to dihydronaphthyridines and related compounds; compositions comprising an effective amount of a dihydronaphthyridine or a related compound; and methods for treating or preventing proliferative diseases comprising the administration of an effective amount of a dihydronaphthyridine or a related compound.